Bone cutting template and method of treating bone fractures

ABSTRACT

A bone cutting template is disclosed and can include a body. A plurality of grooves can be formed along the body and each groove can correspond to an incremental length of the body. The bone cutting template can include a plurality of length stamps along the body. Each of the plurality of length stamps can be adjacent to a corresponding groove.

FIELD OF THE DISCLOSURE

The present disclosure relates generally to orthopedics and orthopedicsurgery. More specifically, the present disclosure relates to devicesused to deliver drugs.

BACKGROUND

An adult human skeleton includes two hundred and six bones. During alifetime a human may fracture one or more of these bones. Some fracturesmay be treated using a casting process. Certain other fractures of longbones may be treated using an intramedullary rod. For example, fracturesof the ulnae, radii, humeri, femora, tibiae, and fibulae can be treatedusing an intramedullary rod. In such cases, the intramedullary rod canbe permanently installed within these bones and the bone can be allowedto heal around the intramedullary rod.

Sometimes, these fractures can also result in a loss of bone, e.g., abone gap, and it may be necessary to fill the bone gap with something topromote new bone growth. It can be advantageous to deliver a therapeuticagent to an area of a bone gap in addition to installing anintramedullary rod.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a plan view of a femur;

FIG. 2 is a front view of a set of therapeutic agent carriers;

FIG. 3 is a rear view of the set of therapeutic agent carriers;

FIG. 4 is an end view of the set of therapeutic agent carriers;

FIG. 5 is a plan view of a therapeutic agent carrier around a bone;

FIG. 6 is a flow chart of a first method of treating a bone fracture;

FIG. 7 is a flow chart of a second method of treating a bone fracture;

FIG. 8 is a front view of a therapeutic agent carrier;

FIG. 9 is an end view of the therapeutic agent carriers;

FIG. 10 is another front view of the therapeutic agent carrier;

FIG. 11 is a front view of a set of bone cutting templates;

FIG. 12 is a rear view of the set of bone cutting templates;

FIG. 13 is an end view of the set of bone cutting templates;

FIG. 14 is a plan view of a bone cutting template handle;

FIG. 15 is an end view of the bone cutting template handle;

FIG. 16 is a plan view of a bone cutting template engaged with a bonecutting template handle; and

FIG. 17 is a flow chart of a third method of treating a bone fracture.

DETAILED DESCRIPTION OF THE DRAWINGS

A bone cutting template is disclosed and can include a body. A pluralityof grooves can be formed along the body and each groove can correspondto an incremental length of the body. The bone cutting template caninclude a plurality of length stamps along the body. Each of theplurality of length stamps can be adjacent to a corresponding groove.

In another embodiment, a method of treating a bone fracture is disclosedand can include retrieving a bone cutting template and trimming aperimeter of a bone void within a bone around the bone cutting template.

In yet another embodiment, a kit for field use is disclosed and caninclude a set of bone cutting templates. Each of the set of bone cuttingtemplates can include a plurality of grooves formed along the body andeach groove can correspond to an incremental length of the body. Also,each of the set of bone cutting templates can include a plurality oflength stamps along the body and each of the plurality of length stampscan be adjacent to a corresponding groove. The kit further includes abone cutting template handle configured to removably engage each of thebone cutting templates.

In still another embodiment, a kit for field use is disclosed and caninclude a set of therapeutic agent carriers. Each of the set oftherapeutic agent carriers can include a body shaped to approximate aportion of a bone and a plurality of grooves formed along the body. Eachgroove can correspond to an incremental length of the body. Each of theset of therapeutic agent carriers can also include a plurality of dosagestamps along the body and each of the plurality of dosage stamps canindicate a dose of therapeutic agent to load the body between an end ofthe body and a groove. The kit can also include a set of bone cuttingtemplates and each of the set of bone cutting templates can include aplurality of grooves formed along the body. Each groove corresponds toan incremental length of the body. Each of the set of bone cuttingtemplates can also include a plurality of length stamps along the bodyand each of the plurality of length stamps can be adjacent to acorresponding groove.

Description of Relevant Anatomy

Referring to FIG. 1, a femur is shown and is generally designated 100.As shown, the femur 100 includes a femoral body 102 that can define aproximal end 104 and a distal end 106. Further, the femur 100 caninclude a femoral head 108 that extends from the proximal end 104 of thefemoral body 102. Further, a neck 110 can be established between thefemoral head 108 and the femoral body 102. In a particular embodiment,the femoral head 108 can fit into a hip socket, a.k.a., an acetabulum(not shown).

As further illustrated in FIG. 1, the proximal end 104 of the femoralbody 102 can include a greater trochanter 112 adjacent to the neck ofthe proximal end 104. Additionally, the distal end 106 of the femoralbody 102 can include a lateral epicondyle 114, a lateral condyle 116, amedial condyle 118, and a medial epicondyle 120. In a particularembodiment, the lateral condyle 116 and the medial condyle 118 canarticulate with a patella (not shown). FIG. 1 also indicates that thefemur 100 can include an adductor tubercle 122.

Description of a Set of Therapeutic Agent Carriers

Referring to FIG. 2 through FIG. 4, a set of therapeutic agent carriersis shown and is generally designated 200. As shown, the set oftherapeutic agent carriers 200 can include a first therapeutic agentcarrier 202, a second therapeutic agent carrier 204, and a thirdtherapeutic agent carrier 206.

In a particular embodiment, the first therapeutic agent carrier 202 caninclude a body 203 having a proximal end 210 and a distal end 212. Thebody 203 of first therapeutic agent carrier 202 can also include aninterior surface 214 and an exterior surface 216. In a particularembodiment, the body 203 of the first therapeutic agent carrier 202 canbe made from a ceramic material, a collagen-ceramic material, adegradable polymer, or a combination thereof.

As illustrated in FIG. 3, the exterior surface 216 of the firsttherapeutic agent carrier 202 can include a plurality of incrementalgrooves 218 from the proximal end 210 of the first therapeutic agentcarrier 202 to the distal end 212 of the therapeutic agent carrier 202.In a particular embodiment, the incremental grooves 218 can indicateincremental lengths along the first therapeutic agent carrier 202. Forexample, if the increment is one-half inch, a user may know that bycutting the first therapeutic agent carrier 202 along the secondincremental groove 218, the first therapeutic agent carrier 202 will beapproximately one inch long. Further, each incremental groove 218 canserve as a guide for a cutting device, e.g., a saw, a knife, a scalpel,scissors, or other similar device.

FIG. 3 further indicates that the therapeutic agent carrier 202 caninclude a dosage stamp 220 adjacent to each incremental groove 218. In aparticular embodiment, each dosage stamp 220 can indicate an amount oftherapeutic agent that can be used to load the first therapeutic agentcarrier 202 to the associated increment groove 218. In this context, theterms “load” or “loading” means wetting, embedding, absorbing, adsorbingor otherwise introducing a therapeutic amount of the desired therapeuticagent onto or into the therapeutic agent carrier, with a “therapeuticamount” being a beneficial dosage based on clinical need. As such, if auser cuts the first therapeutic agent carrier 202 along the secondincremental groove 218, as described above, the user will know that fourcubic centimeters (4.0 cc) of therapeutic agent can be used to properlyload the one inch long portion of the first therapeutic agent carrier202.

The therapeutic agents can include drugs, cellular matters, biologicalfactors, synthetic osteoinductive peptides, synthetic osteopromotivepeptides, or a combination thereof. In a particular embodiment, thedrugs can include antibiotics, analgesics, anti-inflammatory drugs,anti-TNF-alpha, steroids, or a combination thereof. Further, thecellular matters can include bone marrow derived stem cells, lipoderived stem cells, or a combination thereof. Also, the biologicalfactor can include bone morphogenetic protein (BMP), cartilage-derivedmorphogenetic protein (CDMP), platelet derived growth factor (PDGF),insulin-like growth factor (IGF), LIM mineralization protein, fibroblastgrowth factor (FGF), osteoblast growth factor, growth anddifferentiation factor (GDF), vascular endothelial growth factor (VEGF),or a combination thereof. The synthetic osteoinductive peptide or thesynthetic osteopromotive peptide can include a fragment of a thrombinmolecule. Also, the GDF can include GDF-5.

In a particular embodiment, the first therapeutic agent carrier 202 canbe stamped bi-directionally. In other words, the first therapeutic agentcarrier 202 can be marked with a first incremental series of dosagestamps 220 that can be read when the proximal end 210 of the firsttherapeutic agent carrier 202 is up. Also, the first therapeutic agentcarrier 202 can be marked with a second incremental series of dosagestamps 220 that can be read when the distal end 212 of the firsttherapeutic agent carrier 202 is up.

Accordingly, the dosage stamps 220 can indicate the proper dosage oftherapeutic agent that can be used to wet the first therapeutic agentcarrier 202 if the first therapeutic agent carrier 202 is cut from theproximal end 210 or the distal end 212. Further, if the firsttherapeutic agent carrier 202 is cut from the proximal end 210 and usedto fill a bone void, or a bone gap, as described herein, the firsttherapeutic agent carrier 202 can also be cut from the distal end 212and used to fill another bone gap—if the bone gap is the same length orshorter than the remaining portion of the first therapeutic agentcarrier 202.

Referring now to FIG. 4, the first therapeutic agent carrier 202 has across-section that can follow an arc 222 having a central angle 224 thatis substantially equal to ninety degrees (90°). As such, the firsttherapeutic agent carrier 202 has a cross-section that is equal toone-quarter of a hollow cylinder. Further, the exterior surface 216 ofthe first therapeutic agent carrier 202 can define a radius 226. In aparticular embodiment, the radius 226 of the exterior surface 216 can beconfigured to approximate the outer cortex of a bone to be treated. Forexample, the radius 226 of the exterior surface 216 can be in a rangefrom one centimeter (1 cm) to six centimeters (6 cm). Further, fortreating radii bones, the radius 226 can be in a range from twocentimeters (2 cm) to three and one-half centimeters (3.5 cm). Also, fortreating femurs, the radius 226 can be in a range from two centimeters(2 cm) to four centimeters (4 cm). Also, the first therapeutic agentcarrier 202 can have a thickness 228. In a particular embodiment, thethickness 228 of the first therapeutic agent carrier 202 can be in arange from one centimeter (1 cm) to six centimeters (6 cm).

In a particular embodiment, the second therapeutic agent carrier 204 caninclude a body 205 having a proximal end 230 and a distal end 232. Thebody 205 of the second therapeutic agent carrier 204 can also include aninterior surface 234 and an exterior surface 236. In a particularembodiment, the body 205 of the second therapeutic agent carrier 204 canbe made from a ceramic material, a collagen-ceramic material, adegradable polymer, or a combination thereof.

As illustrated in FIG. 3, the exterior surface 236 of the secondtherapeutic agent carrier 204 can include a plurality of incrementalgrooves 238 from the proximal end 230 of the second therapeutic agentcarrier 204 to the distal end 232 of the therapeutic agent carrier 204.In a particular embodiment, the incremental grooves 238 can indicateincremental lengths along the second therapeutic agent carrier 204. Forexample, if the increment is one-half inch, a user may know that bycutting the second therapeutic agent carrier 204 along the secondincremental groove 238, the second therapeutic agent carrier 204 will beapproximately one inch long. Further, each incremental groove 238 canserve as a guide for a cutting device, e.g., a saw, a knife, a scalpel,scissors, or other similar device.

FIG. 3 further indicates that the second therapeutic agent carrier 204can include a dosage stamp 240 adjacent to each incremental groove 238.In a particular embodiment, each dosage stamp 240 can indicate an amountof therapeutic agent that can be used to load the second therapeuticagent carrier 204 to the associated increment groove 238. In thiscontext, the terms “load” or “loading” means wetting, embedding,absorbing, adsorbing, or otherwise introducing a therapeutic amount ofthe desired therapeutic agent onto or into the therapeutic agentcarrier, with a “therapeutic amount” being a beneficial dosage based onclinical need. As such, if a user cuts the second therapeutic agentcarrier 204 along the second incremental groove 238, as described above,the user will know that four cubic centimeters (4.0 cc) of therapeuticagent can be used to properly load the one inch long portion of thesecond therapeutic agent carrier 204.

The therapeutic agents can include drugs, cellular matters, biologicalfactors, synthetic osteoinductive peptides, synthetic osteopromotivepeptides, or a combination thereof. In a particular embodiment, thedrugs can include antibiotics, analgesics, anti-inflammatory drugs,anti-TNF-alpha, steroids, or a combination thereof. Further, thecellular matters can include bone marrow derived stem cells, lipoderived stem cells, or a combination thereof. Also, the biologicalfactor can include bone morphogenetic protein (BMP), cartilage-derivedmorphogenetic protein (CDMP), platelet derived growth factor (PDGF),insulin-like growth factor (IGF), LIM mineralization protein, fibroblastgrowth factor (FGF), osteoblast growth factor, growth anddifferentiation factor (GDF), vascular endothelial growth factor (VEGF),or a combination thereof. The synthetic osteoinductive peptide or thesynthetic osteopromotive peptide can include a fragment of a thrombinmolecule. Also, the GDF can include GDF-5.

In a particular embodiment, the second therapeutic agent carrier 204 canbe stamped bi-directionally. In other words, the second therapeuticagent carrier 204 can be marked with a second incremental series ofdosage stamps 240 that can be read when the proximal end 230 of thesecond therapeutic agent carrier 204 is up. Also, the second therapeuticagent carrier 204 can be marked with a second incremental series ofdosage stamps 240 that can be read when the distal end 232 of the secondtherapeutic agent carrier 204 is up.

Accordingly, the dosage stamps 240 can indicate the proper dosage oftherapeutic agent that can be used to wet the second therapeutic agentcarrier 204 if the second therapeutic agent carrier 204 is cut from theproximal end 230 or the distal end 232. Further, if the secondtherapeutic agent carrier 204 is cut from the proximal end 230 and usedto fill a bone gap as described herein, the second therapeutic agentcarrier 204 can also be cut from the distal end 232 and used to fillanother bone gap—if the bone gap is the same length or shorter than theremaining portion of the second therapeutic agent carrier 204.

Referring now to FIG. 4, the second therapeutic agent carrier 204 has across-section that can follow an arc 242 having a central angle 244 thatis substantially equal to one hundred and twenty degrees (120°). Assuch, the second therapeutic agent carrier 204 has a cross-section thatis equal to one-third of a hollow cylinder. Further, the exteriorsurface 236 of the second therapeutic agent carrier 204 can define aradius 246. In a particular embodiment, the radius 246 of the exteriorsurface 236 can be configured to approximate the outer cortex of a boneto be treated. For example, the radius 246 of the exterior surface 236can be in a range from one centimeter (1 cm) to six centimeters (6 cm).Further, for treating radii bones, the radius 246 can be in a range fromtwo centimeters (2 cm) to three and one-half centimeters (3.5 cm). Also,for treating femurs, the radius 246 can be in a range from twocentimeters (2 cm) to four centimeters (4 cm). Also, the secondtherapeutic agent carrier 204 can have a thickness 248. In a particularembodiment, the thickness 248 of the second therapeutic agent carrier204 can be in a range from one centimeter (1 cm) to six centimeters (6cm).

In a particular embodiment, the third therapeutic agent carrier 206 caninclude a body 207 having a proximal end 250 and a distal end 252. Thebody 207 of the third therapeutic agent carrier 206 can also include aninterior surface 254 and an exterior surface 256. In a particularembodiment, the body 207 of the third therapeutic agent carrier 206 canbe made from a ceramic material, a collagen-ceramic material, adegradable polymer, or a combination thereof.

As illustrated in FIG. 3,. the exterior surface 256 of the thirdtherapeutic agent carrier 206 can include a plurality of incrementalgrooves 258 from the proximal end 250 of the third therapeutic agentcarrier 206 to the distal end 252 of the therapeutic agent carrier 206.In a particular embodiment, the incremental grooves 258 can indicateincremental lengths along the third therapeutic agent carrier 206. Forexample, if the increment is one-half inch, a user may know that bycutting the third therapeutic agent carrier 206 along the secondincremental groove 258, the third therapeutic agent carrier 206 will beapproximately one inch long. Further, each incremental groove 258 canserve as a guide for a cutting device, e.g., a saw, a knife, a scalpel,scissors, or other similar device.

FIG. 3 further indicates that the therapeutic agent carrier 206 caninclude a dosage stamp 260 adjacent to each incremental groove 258. In aparticular embodiment, each dosage stamp 260 can indicate an amount oftherapeutic agent that can be used to load the third therapeutic agentcarrier 206 to the associated increment groove 258. In this context, theterms “load” or “loading” means wetting, embedding, absorbing,adsorbing, or otherwise introducing a therapeutic amount of the desiredtherapeutic agent onto or into the therapeutic agent carrier, with a“therapeutic amount” being a beneficial dosage based on clinical need.As such, if a user cuts the third therapeutic agent carrier 206 alongthe second incremental groove 258, as described above, the user willknow that four cubic centimeters (4.0 cc) of therapeutic agent can beused to properly load the one inch long portion of the third therapeuticagent carrier 206.

The therapeutic agents can include drugs, cellular matters, biologicalfactors, synthetic osteoinductive peptides, synthetic osteopromotivepeptides, or a combination thereof. In a particular embodiment, thedrugs can include antibiotics, analgesics, anti-inflammatory drugs,anti-TNF-alpha, steroids, or a combination thereof. Further, thecellular matters can include bone marrow derived stem cells, lipoderived stem cells, or a combination thereof. Also, the biologicalfactor can include bone morphogenetic protein (BMP), cartilage-derivedmorphogenetic protein (CDMP), platelet derived growth factor (PDGF),insulin-like growth factor (IGF), LIM mineralization protein, fibroblastgrowth factor (FGF), osteoblast growth factor, growth anddifferentiation factor (GDF), vascular endothelial growth factor (VEGF),or a combination thereof. The synthetic osteoinductive peptide or thesynthetic osteopromotive peptide can include a fragment of a thrombinmolecule. Also, the GDF can include GDF-5.

In a particular embodiment, the third therapeutic agent carrier 206 canbe stamped bi-directionally. In other words, the third therapeutic agentcarrier 206 can be marked with a third incremental series of dosagestamps 260 that can be read when the proximal end 250 of the thirdtherapeutic agent carrier 206 is up. Also, the third therapeutic agentcarrier 206 can be marked with a second incremental series of dosagestamps 260 that can be read when the distal end 252 of the thirdtherapeutic agent carrier 206 is up.

Accordingly, the dosage stamps 260 can indicate the proper dosage oftherapeutic agent that can be used to wet the third therapeutic agentcarrier 206 if the third therapeutic agent carrier 206 is cut from theproximal end 250 or the distal end 252. Further, if the thirdtherapeutic agent carrier 206 is cut from the proximal end 250 and usedto fill a bone gap as described herein, the third therapeutic agentcarrier 206 can also be cut from the distal end 252 and used to fillanother bone gap - if the bone gap is the same length or shorter thanthe remaining portion of the third therapeutic agent carrier 206.

Referring now to FIG. 4, the third therapeutic agent carrier 206 has across-section that can follow an arc 262 having a central angle 264 thatis substantially equal to one hundred and eighty degrees (180°). Assuch, the third therapeutic agent carrier 206 has a cross-section thatis equal to one-half of a hollow cylinder, i.e., the third therapeuticagent carrier 206 has a cross-section that is equal to a hollowsemi-cylinder. Further, the exterior surface 256 of the thirdtherapeutic agent carrier 206 can define a radius 266. In a particularembodiment, the radius 266 of the exterior surface 256 can be configuredto approximate the outer cortex of a bone to be treated. For example,the radius 266 of the exterior surface 256 can be in a range from onecentimeter (1 cm) to six centimeters (6 cm). Further, for treating radiibones, the radius 266 can be in a range from two centimeters (2 cm) tothree and one-half centimeters (3.5 cm). Also, for treating femurs, theradius 266 can be in a range from two centimeters (2 cm) to fourcentimeters (4 cm). Also, the third therapeutic agent carrier 206 canhave a thickness 268. In a particular embodiment, the thickness 268 ofthe third therapeutic agent carrier 206 can be in a range from onecentimeter (1 cm) to six centimeters (6 cm).

Description of a Therapeutic Agent Carrier Installed within a BoneDefect

Referring now to FIG. 5, a bone is shown and is generally designated500. The bone 500 can include a defect (not shown) into or over which atherapeutic agent carrier 502 can be inserted, disposed, or otherwisecover. In a particular embodiment the bone defect can be a gap in whichbone has been removed or lost due to injury. Further, in a particularembodiment, the therapeutic agent carrier 502 can be a therapeutic agentcarrier according to one or more of the embodiments described herein.

As depicted, the therapeutic agent carrier 502 can be installedsubstantially within the bone defect to replace the missing bone.Further, the therapeutic agent carrier 502 can be held in place by oneor more sutures 504, 506 that can be wound around, or otherwise affixedto, the therapeutic agent carrier 502 and the bone 500. Also, in aparticular embodiment, the therapeutic agent carrier 502 can be used totreat a fracture in conjunction with an intramedullary device 508, e.g.,an intramedullary rod, an intramedullary nail, or a combination thereof.

Description of a First Method of Treating a Bone Fracture

Referring to FIG. 6, a method of treating a bone fracture is shown andcommences at block 600. At block 600, a bone gap due to a fracture inthe bone can be exposed. At block 602, the bone gap can be measured.Further, at block 604, a therapeutic agent carrier can be selected froma set of therapeutic agent carriers. The therapeutic agent carrier canbe selected based on the type of bone having the fracture, the size ofthe bone, the size of the bone gap, or a combination thereof.

Proceeding to block 606, the selected therapeutic agent carrier can beretrieved from the set of therapeutic agent carriers. At block 608, thetherapeutic agent carrier can be cut to size. For example, thetherapeutic agent carrier can be sized based on the size of the bone gapmeasured above. Further, the therapeutic agent carrier can be trimmed tofit the shape of the bone gap. Moving to block 610, the therapeuticagent carrier can be loaded with a therapeutic agent. At block 612, thetherapeutic agent carrier can be positioned within the bone gap.Thereafter, at block 614, the therapeutic agent carrier can be suturedin place.

Continuing to block 616, the surgical wound associated with exposing thebone gap can be closed. The surgical wound can be closed by simplyallowing the patient's skin to close due to the elasticity of the skin.Alternatively, the surgical wound can be closed using sutures, surgicalstaples, or any other suitable surgical technique well known in the art.At block 618, post-operative care can be initiated. The method then endsat state 620.

In a particular embodiment, as indicated in FIG. 6, the therapeuticagent carrier can be wetted prior to placement within the bone gap.However, in an alternative embodiment, the therapeutic agent carrier canbe wetted after placement within the bone gap.

Description of a Second Method of Treating a Bone Fracture

Referring to FIG. 7, a second method of treating a bone fracture isshown and commences at block 700. At block 700, a bone gap due to afracture in the bone can be exposed. At block 702, the bone gap can bemeasured. Further, at block 704, a therapeutic agent carrier can beselected from a set of therapeutic agent carriers. The therapeutic agentcarrier can be selected based on the type of bone having the fracture,the size of the bone, the size of the bone gap, or a combinationthereof.

Proceeding to block 706, the selected therapeutic agent carrier can beretrieved from the set of therapeutic agent carriers. At block 708, thetherapeutic agent carrier can be cut to size. For example, thetherapeutic agent carrier can be sized based on the size of the bone gapmeasured above.

At block 710, an end of a bone can be accessed. Further, at block 712, apilot hole can be drilled in the end of the bone. Moving to block 714, aguide wire, or guide pin, can be inserted into a bone canal within thebone through the pilot hole. Thereafter, at block 716, a bone reamer canbe inserted into the bone canal over the guide wire.

Proceeding to block 718, the bone canal can be reamed using the bonereamer. At block 720, the bone reamer can be removed from the bonecanal. Moving to block 722, an intramedullary rod, or intramedullarynail, can be inserted into the bone canal over the guide wire. At block724, the guide wire can be removed. Further, at block 726, thetherapeutic agent carrier can be wetted with a therapeutic agent. Atblock 728, the therapeutic agent can be positioned around theintramedullary rod, or intramedullary nail, within the bone gap.Thereafter, at block 730, the therapeutic agent carrier can be suturedin place.

Continuing to block 732, the surgical wound associated with exposing thebone gap can be closed. The surgical wound can be closed by simplyallowing the patient's skin to close due to the elasticity of the skin.Alternatively, the surgical wound can be closed using sutures, surgicalstaples, or any other suitable surgical technique well known in the art.At block 734, post-operative care can be initiated. The method then endsat state 736.

Description of an Alternative Embodiment of a Therapeutic Agent Carrier

Referring to FIG. 8 through FIG. 10, an alternative embodiment of atherapeutic agent carrier is shown and is generally designated 800. Asshown, the therapeutic agent carrier 800 can include a body 802 that canhave a cross-section that is hollow and generally cylindrical.Alternatively, the body 802 of the therapeutic agent carrier 800 canhave a cross-section that is generally prismatic shape. Moreover, thebody 802 of the therapeutic agent carrier 800 can have any generallypolyhedral shape with a central opening formed therein.

In a particular embodiment, the body 802 of the therapeutic agentcarrier 800 can include a proximal end 804 and a distal end 806. Thebody 802 of the therapeutic agent carrier 800 can also include aninterior surface 808 and an exterior surface 810.

As illustrated in FIG. 8, the exterior surface 810 of the therapeuticagent carrier 800 can include a plurality of lateral grooves 812 fromthe proximal end 804 of the body 802 to the distal end 806 of the body802. In a particular embodiment, the lateral grooves 812 can indicateincremental lengths along the body 802 of the therapeutic agent carrier800. For example, if the increment is one-half inch, a user may knowthat by cutting the therapeutic agent carrier 800 along the secondincremental groove 812, the therapeutic agent carrier 800 will beapproximately one inch long. Further, each lateral groove 812 can serveas a guide for a cutting device, e.g., a saw, a knife, a scalpel,scissors, or other similar device.

FIG. 8 also shows that the body 802 of the therapeutic agent carrier 800can include a plurality of longitudinal grooves 814 along the length ofthe body 802. As illustrated in FIG. 9, the longitudinal grooves 814 canbe spaced radially around the body 802 of the therapeutic agent carrier800 and each longitudinal groove 814 can include a label 816. Thelongitudinal grooves 814 can be labeled so that by cutting similarlylabeled longitudinal grooves 814 the therapeutic agent carrier 800 canbe cut into halves, thirds, or quarters. For example, two longitudinalgrooves 814 can be labeled “½”, three longitudinal grooves 814 can belabeled “⅓”, and four longitudinal grooves can be labeled “¼”.Accordingly, the therapeutic agent carrier 800 shown in FIG. 8 can becut into pieces that are sized and shaped similarly to the therapeuticagent carriers 202, 204, 206 shown in FIG. 2 through FIG. 4.

Referring to FIG. 10, a container is shown and is designated 1000. Asillustrated, the container 1000 includes a base 1002 and a lid 1004. Ina particular embodiment, the therapeutic agent carrier 800 can be placedwithin the container 1000 and the container 1000 can be filled with atherapeutic agent 1006. The therapeutic agent carrier 800 can be porousand as such, the therapeutic agent carrier 800 can be loaded with atleast a portion of the therapeutic agent 1006. During surgery, asurgeon, or nurse, can retrieve the therapeutic agent carrier 800 fromthe container 1000 and cut the therapeutic agent carrier 800 to a sizethat can be fitted into a bone gap. The therapeutic agent carrier 800can be pre-loaded due to soaking in the therapeutic agent carrier 800.

In a particular embodiment, any of the therapeutic agent carriers 202,204, 206 shown in FIG. 2 through FIG. 4 can also be placed within thecontainer 1000 to load in the therapeutic agent 1006. The porosity ofthe therapeutic agent carriers 202, 204, 206 can be such that a user candetermine the dose of material within the therapeutic agent carrier 202,204, 206 based on the largest dosage stamp 220, 240, 260 on thetherapeutic agent carrier 202, 204, 206. For example, if the firsttherapeutic agent carrier 202 is retrieved from the container 1000 andcut along the fourth groove 218, a user can determine that the dose ofthe therapeutic agent impregnated within that portion of the firsttherapeutic agent carrier 202 is eight cubic centimeters (8 cc).

Alternatively, the therapeutic agent carriers 202, 204, 206 can bepre-loaded with a therapeutic agent during manufacturing and the dosagestamps 220, 240, 260 can indicate a dosage available in the pre-loadedtherapeutic agent carrier 202, 204, 206. Additionally, the grooves 218,238, 258 can be lines along which the therapeutic agent carriers 202,204, 206.

The therapeutic agents can include drugs, cellular matters, biologicalfactors, synthetic osteoinductive peptides, synthetic osteopromotivepeptides, or a combination thereof. In a particular embodiment, thedrugs can include antibiotics, analgesics, anti-inflammatory drugs,anti-TNF-alpha, steroids, or a combination thereof. Further, thecellular matters can include bone marrow derived stem cells, lipoderived stem cells, or a combination thereof. Also, the biologicalfactor can include bone morphogenetic protein (BMP), cartilage-derivedmorphogenetic protein (CDMP), platelet derived growth factor (PDGF),insulin-like growth factor (IGF), LIM mineralization protein, fibroblastgrowth factor (FGF), osteoblast growth factor, growth anddifferentiation factor (GDF), vascular endothelial growth factor (VEGF),or a combination thereof. The synthetic osteoinductive peptide or thesynthetic osteopromotive peptide can include a fragment of a thrombinmolecule. Also, the GDF can include GDF-5.

Description of a Set of Bone Cutting Templates

Referring to FIG. 11 through FIG. 13, a set of bone cutting templates isshown and is generally designated 1100. As shown, the set of bonecutting templates 1100 can include a first bone cutting template 1102, asecond bone cutting template 1104, and a third bone cutting template1106.

In a particular embodiment, the first bone cutting template 1102 caninclude a body 1103 having a proximal end 1110 and a distal end 1112.The body 1103 of first bone cutting template 1102 can also include aninterior surface 1114 and an exterior surface 1116. In a particularembodiment, the body 1103 of the first bone cutting template 1102 can bemade from one or more biocompatible materials. For example, thematerials can be metal containing materials, polymer materials, orcomposite materials that include metals, polymers, or combinations ofmetals and polymers.

In a particular embodiment, the metal containing materials can bemetals. Further, the metal containing materials can be ceramics. Also,the metals can be pure metals or metal alloys. The pure metals caninclude titanium. Moreover, the metal alloys can include stainlesssteel, a cobalt-chrome-molybdenum alloy, e.g., ASTM F-999 or ASTM F-75,a titanium alloy, or a combination thereof.

The polymer materials can include polyurethane materials, polyolefinmaterials, polyaryletherketone (PAEK) materials, or a combinationthereof. Further, the polyolefin materials can include polypropylene,polyethylene, halogenated polyolefin, flouropolyolefin, or a combinationthereof. The polyaryletherketon (PAEK) materials can includepolyetherketone (PEK), polyetheretherketone (PEEK),polyetherketoneketone (PEKK), polyetherketoneetherketoneketone (PEKEKK),or a combination thereof. Alternatively, the body 1103 can be made fromany other substantially rigid biocompatible materials.

As illustrated in FIG. 12, the exterior surface 1116 of the first bonecutting template 1102 can include a plurality of incremental grooves1118 from the proximal end 1110 of the first bone cutting template 1102to the distal end 1112 of the bone cutting template 1102. In aparticular embodiment, the incremental grooves 1118 can indicateincremental lengths along the first bone cutting template 1102.

FIG. 12 further indicates that the bone cutting template 1102 caninclude a length stamp 1120 adjacent to each incremental groove 1118. Ina particular embodiment, each length stamp 1120 can indicate a lengthalong the bone cutting template 1102.

In a particular embodiment, the first bone cutting template 1102 can bestamped bi-directionally. In other words, the first bone cuttingtemplate 1102 can be marked with a first incremental series of lengthstamps 1120 that can be read from a first side of the first bone cuttingtemplate 1102 (i.e., length stamps can be oriented in an uprightposition relative to the first side of the template). Also, the firstbone cutting template 1102 can be marked with a second incrementalseries of length stamps 1120 that can be read from a second side of thefirst bone cutting template 1102 (i.e., length stamps can be oriented inan upright position relative to the second side of the template).

During surgery, the first bone cutting template 1102 can be placed overa bone defect, or bone void. Further, a surgeon can use the first bonecutting template 1102 as a guide to trim the perimeter of the bonedefect to allow a therapeutic agent carrier, e.g., a therapeutic agentcarrier according to one or more of the embodiments described herein, tobe fitted into the opening created. The surgeon can trim one edge of thebone defect using the first bone cutting template 1102 and then, thesurgeon may slide the first bone cutting template 1102 relative to thebone defect and align one of the incremental grooves 1118 with thetrimmed edge in order to create an opening that is shorter than theoverall length of the first bone cutting template 1102. Further, thesurgeon can measure the size of the opening created using the lengthstamps 1120 along the first bone cutting template 1102. The lengthstamps 1120 can be used to measure a bone gap before or after the bonearound the bone gap is cut around the template.

FIG. 12 further indicates that the first bone cutting template 1102 caninclude a central opening 1122 therethrough. In a particular embodiment,the central opening 1122 is keyed to a tip of a bone cutting templatehandle, described below. In other words, the central opening 1122 of thefirst bone cutting template 1102 is sized and shaped to receive the tipof the bone cutting template handle and removably engage the tip of thebone cutting template handle.

Referring now to FIG. 13, the first bone cutting template 1102 has across-section that can follow an arc 1124 having a central angle 1126that is substantially equal to ninety degrees (90°). As such, the firstbone cutting template 1102 has a cross-section that is equal toone-quarter of a hollow cylinder. Further, the interior surface 1114 ofthe first bone cutting template 1102 can define a radius 1128. In aparticular embodiment, the radius 1128 of the exterior surface 1116 canbe configured to approximate the outer cortex of a bone to be treated.For example, the radius 1128 of the interior surface 1114 can be in arange from one centimeter (1 cm) to six centimeters (6 cm). Further, fortreating radii bones, the radius 1128 can be in a range from twocentimeters (2 cm) to three and one-half centimeters (3.5 cm). Also, fortreating femurs, the radius 1128 can be in a range from two centimeters(2 cm) to four centimeters (4 cm).

In a particular embodiment, the second bone cutting template 1104 caninclude a body 1105 having a proximal end 1130 and a distal end 1132.The body 1105 of second bone cutting template 1104 can also include aninterior surface 1134 and an exterior surface 1136. In a particularembodiment, the body 1105 of the second bone cutting template 1104 canbe made from one or more biocompatible materials. For example, thematerials can be metal containing materials, polymer materials, orcomposite materials that include metals, polymers, or combinations ofmetals and polymers.

In a particular embodiment, the metal containing materials can bemetals. Further, the metal containing materials can be ceramics. Also,the metals can be pure metals or metal alloys. The pure metals caninclude titanium. Moreover, the metal alloys can include stainlesssteel, a cobalt-chrome-molybdenum alloy, e.g., ASTM F-999 or ASTM F-75,a titanium alloy, or a combination thereof.

The polymer materials can include polyurethane materials, polyolefinmaterials, polyaryletherketone (PAEK) materials, or a combinationthereof. Further, the polyolefin materials can include polypropylene,polyethylene, halogenated polyolefin, flouropolyolefin, or a combinationthereof. The polyaryletherketon (PAEK) materials can includepolyetherketone (PEK), polyetheretherketone (PEEK),polyetherketoneketone (PEKK), polyetherketoneetherketoneketone (PEKEKK),or a combination thereof. Alternatively, the body 1105 can be made fromany other substantially rigid biocompatible materials.

As illustrated in FIG. 12, the exterior surface 1136 of the second bonecutting template 1104 can include a plurality of incremental grooves1138 from the proximal end 1130 of the second bone cutting template 1104to the distal end 1132 of the bone cutting template 1104. In aparticular embodiment, the incremental grooves 1138 can indicateincremental lengths along the second bone cutting template 1104.

FIG. 12 further indicates that the second bone cutting template 1104 caninclude a length stamp 1140 adjacent to each incremental groove 1138. Ina particular embodiment, each length stamp 1140 can indicate a lengthalong the bone cutting template 1104.

In a particular embodiment, the second bone cutting template 1104 can bestamped bi-directionally. In other words, the second bone cuttingtemplate 1104 can be marked with a first incremental series of lengthstamps 1140 that can be read from a first side of the second bonecutting template 1104. Also, the second bone cutting template 1104 canbe marked with a second incremental series of length stamps 1140 thatcan be read from a second side of the second bone cutting template 1104.

During surgery, the second bone cutting template 1104 can be place overa bone defect, or bone void. Further, a surgeon can use the second bonecutting template 1104 as a guide to trim the perimeter of the bonedefect to allow a therapeutic agent carrier, e.g., a therapeutic agentcarrier according to one or more of the embodiments described herein, tobe fitted into the opening created. The surgeon can trim one edge of thebone defect using the second bone cutting template 1104 and then, thesurgeon may slide the second bone cutting template 1104 relative to thebone defect and align one of the incremental grooves 1138 with thetrimmed edge in order to create an opening that is shorter than theoverall length of the second bone cutting template 1104. Further, thesurgeon can measure the size of the opening created using the lengthstamps 1140 along the second bone cutting template 1104. The lengthstamps 1140 can be used to measure a bone gap before or after the bonearound the bone gap is cut around the template.

FIG. 12 further indicates that the second bone cutting template 1104 caninclude a central opening 1142 therethrough. In a particular embodiment,the central opening 1142 is keyed to a tip of a bone cutting templatehandle, described below. In other words, the central opening 1142 of thesecond bone cutting template 1104 is sized and shaped to receive the tipof the bone cutting template handle and removably engage the tip of thebone cutting template handle.

Referring to FIG. 13, the second bone cutting template 1104 has across-section that can follow an arc 1144 having a central angle 1146that is substantially equal to one hundred and twenty degrees (120°). Assuch, the second bone cutting template 1104 has a cross-section that isequal to one-third of a hollow cylinder. Further, the interior surface1134 of the second bone cutting template 1104 can define a radius 1148.In a particular embodiment, the radius 1148 of the interior surface 1134can be configured to approximate the outer cortex of a bone to betreated. For example, the radius 1148 of the interior surface 1134 canbe in a range from one centimeter (1 cm) to six centimeters (6 cm).Further, for treating radii bones, the radius 1148 can be in a rangefrom two centimeters (2 cm) to three and one-half centimeters (3.5 cm).Also, for treating femurs, the radius 1148 can be in a range from twocentimeters (2 cm) to four centimeters (4 cm).

In a particular embodiment, the third bone cutting template 1106 caninclude a body 1107 having a proximal end 1150 and a distal end 1152.The body 1107 of third bone cutting template 1106 can also include aninterior surface 1154 and an exterior surface 1156. In a particularembodiment, the body 1107 of the third bone cutting template 1106 can bemade from one or more biocompatible materials. For example, thematerials can be metal containing materials, polymer materials, orcomposite materials that include metals, polymers, or combinations ofmetals and polymers.

In a particular embodiment, the metal containing materials can bemetals. Further, the metal containing materials can be ceramics. Also,the metals can be pure metals or metal alloys. The pure metals caninclude titanium. Moreover, the metal alloys can include stainlesssteel, a cobalt-chrome-molybdenum alloy, e.g., ASTM F-999 or ASTM F-75,a titanium alloy, or a combination thereof.

The polymer materials can include polyurethane materials, polyolefinmaterials, polyaryletherketone (PAEK) materials, or a combinationthereof. Further, the polyolefin materials can include polypropylene,polyethylene, halogenated polyolefin, flouropolyolefin, or a combinationthereof. The polyaryletherketon (PAEK) materials can includepolyetherketone (PEK), polyetheretherketone (PEEK),polyetherketoneketone (PEKK), polyetherketoneetherketoneketone (PEKEKK),or a combination thereof. Alternatively, the body 1107 can be made fromany other substantially rigid biocompatible materials.

As illustrated in FIG. 12, the exterior surface 1156 of the third bonecutting template 1106 can include a plurality of incremental grooves1158 from the proximal end 1150 of the third bone cutting template 1106to the distal end 1152 of the bone cutting template 1106. In aparticular embodiment, the incremental grooves 1158 can indicateincremental lengths along the third bone cutting template 1106.

FIG. 12 further indicates that the bone cutting template 1106 caninclude a length stamp 1160 adjacent to each incremental groove 1158. Ina particular embodiment, each length stamp 1160 can indicate a lengthalong the bone cutting template 1106.

In a particular embodiment, the third bone cutting template 1106 can bestamped bi-directionally. In other words, the third bone cuttingtemplate 1106 can be marked with a first incremental series of lengthstamps 1160 that can be read from a first side of the third bone cuttingtemplate 1106. Also, the third bone cutting template 1106 can be markedwith a second incremental series of length stamps 1160 that can be readfrom a second side of the third bone cutting template 1106.

During surgery, the third bone cutting template 1106 can be place over abone defect, or bone void. Further, a surgeon can use the third bonecutting template 1106 as a guide to trim the perimeter of the bonedefect to allow a therapeutic agent carrier, e.g., a therapeutic agentcarrier according to one or more of the embodiments described herein, tobe fitted into the opening created. The surgeon can trim one edge of thebone defect using the third bone cutting template 1106 and then, thesurgeon may slide the third bone cutting template 1106 relative to thebone defect and align one of the incremental grooves 1158 with thetrimmed edge in order to create an opening that is shorter than theoverall length of the third bone cutting template 1106. Further, thesurgeon can measure the size of the opening created using the lengthstamps 1160 along the third bone cutting template 1106. The lengthstamps 1160 can be used to measure a bone gap before or after the bonearound the bone gap is cut around the template.

FIG. 12 further indicates that the third bone cutting template 1106 caninclude a central opening 1162 therethrough. In a particular embodiment,the central opening 1162 is keyed to a tip of a bone cutting templatehandle, described below. In other words, the central opening 1162 of thethird bone cutting template 1106 is sized and shaped to receive the tipof the bone cutting template handle and removably engage the tip of thebone cutting template handle.

Still referring to FIG. 13, the third bone cutting template 1106 has across-section that can follow an arc 1164 having a central angle 1166that is substantially equal to one hundred and eighty degrees (180°). Assuch, the third bone cutting template 1106 has a cross-section that isequal to one-half of a hollow cylinder, i.e., the third bone cuttingtemplate 1106 has a cross-section that is equal to a hollowsemi-cylinder. Further, the interior surface 1154 of the third bonecutting template 1106 can define a radius 1168. In a particularembodiment, the radius 1168 of the interior surface 1154 can beconfigured to approximate the outer cortex of a bone to be treated. Forexample, the radius 1168 of the interior surface 1154 can be in a rangefrom one centimeter (1 cm) to six centimeters (6 cm). Further, fortreating radii bones, the radius 1168 can be in a range from twocentimeters (2 cm) to three and one-half centimeters (3.5 cm). Also, fortreating femurs, the radius 1168 can be in a range from two centimeters(2 cm) to four centimeters (4 cm).

Description of a Bone Cutting Template Handle

Referring to FIG. 14 and FIG. 15, a bone cutting template handle isshown and is generally designated 1400. As shown, the bone cuttingtemplate handle 1400 can include a body 1402 that can include a proximalend 1404 and a distal end 1406. A handle 1408 can be attached to theproximal end 1404 of the body 1402.

Further, as shown in FIG. 15, the distal end 1406 of the body 1402 caninclude a tip 1410 that is keyed to the bone cutting templates 1102,1104, 1106. In other words, the tip 1410 of the bone cutting templatehandle 1400 is sized and shaped to be inserted into the central opening1122, 1142, 1162 of each bone cutting template 1102, 1104, 1106. Assuch, the tip 1410 of the bone cutting template handle 1400 can beinserted into a central opening 1122, 1142, 1162 of a bone cuttingtemplate 1102, 1104, 1106 and the bone cutting template handle 1400 canbe rotated to lock the tip 1410 of the bone cutting template handle 1400within a bone cutting template, e.g., the third bone cutting template1106, as shown in FIG. 16.

During surgery, a surgeon can select an appropriate bone cuttingtemplate 1102, 1104, 1106 from a set of bone cutting templates 1100 anduse the bone cutting template 1102, 1104, 1106 to trim a bone gap sothat a therapeutic agent carrier, e.g., a therapeutic agent carrieraccording to one or more of the embodiments described herein, can fitwithin the bone gap.

Description of a Third Method of Treating a Bone Fracture

Referring to FIG. 17, a third method of treating a bone fracture isshown and commences at block 1700. At block 1700, a bone gap due to afracture in the bone can be exposed. At block 1702, a bone cuttingtemplate can be selected. Thereafter, at block 1704, the selected bonecutting template can be retrieved. In a particular embodiment, theselected bone cutting template can be retrieved by engaging a bonecutting template handle with the selected bone cutting template. Atblock 1706, the bone gap can be trimmed around the bone cuttingtemplate. In a particular embodiment, the bone gap can be trimmed usinga medical saw. At block 1708, the bone cutting template can be removedfrom the surgical field. Also, at block 1710, any bone fragments can beremoved from the surgical field.

Moving to block 1712, a therapeutic agent carrier can be selected from aset of therapeutic agent carriers. The therapeutic agent carrier can beselected based on the type of bone having the fracture, the size of thebone, the size of the bone gap, or a combination thereof. At block 1714,the selected therapeutic agent carrier can be retrieved from the set oftherapeutic agent carriers. Further, at block 1716, the therapeuticagent carrier can be cut to size. For example, the therapeutic agentcarrier can be sized based on the size of the bone gap measured above.

At block 1718, an end of a bone can be accessed. Further, at block 1720,a pilot hole can be drilled in the end of the bone. Moving to block1722, a guide wire, or guide pin, can be inserted into a bone canalwithin the bone through the pilot hole. Thereafter, at block 1724, abone reamer can be inserted into the bone canal over the guide wire.

Proceeding to block 1726, the bone canal can be reamed using the bonereamer. At block 1728, the bone reamer can be removed from the bonecanal. Moving to block 1730, an intramedullary rod, or intramedullarynail, can be inserted into the bone canal over the guide wire. At block1732, the guide wire can be removed. Further, at block 1734, thetherapeutic agent carrier can be wetted with a therapeutic agent. Atblock 1736, the therapeutic agent can be positioned around theintramedullary rod, or intramedullary nail, within the bone gap.Thereafter, at block 1738, the therapeutic agent carrier can be suturedin place.

Continuing to block 1740, the surgical wound associated with exposingthe bone gap can be closed. The surgical wound can be closed by simplyallowing the patient's skin to close due to the elasticity of the skin.Alternatively, the surgical wound can be closed using sutures, surgicalstaples, or any other suitable surgical technique well known in the art.At block 1742, post-operative care can be initiated. The method thenends at state 1744.

Conclusion

With the configuration of structure described above, the therapeuticagent carrier provides a device that can be used to deliver atherapeutic agent to an area within a bone defect. A therapeutic agentcarrier can be selected from a group of therapeutic agent carriers andcut to size to fit within the bone defect. Further, prior to positioningwithin the bone defect, the therapeutic agent carrier can be loaded witha therapeutic agent. Also, the bone cutting templates provide a devicethat can be used to trim a bone defect prior to installing thetherapeutic agent carrier.

The above-disclosed subject matter is to be considered illustrative, andnot restrictive, and the appended claims are intended to cover all suchmodifications, enhancements, and other embodiments that fall within thetrue spirit and scope of the present invention. Thus, to the maximumextent allowed by law, the scope of the present invention is to bedetermined by the broadest permissible interpretation of the followingclaims and their equivalents, and shall not be restricted or limited bythe foregoing detailed description.

What is claimed is:
 1. A bone cutting template, comprising: a bodyhaving an axis, an axial length and an axial cross-sectional shape thatis semi-cylindrical along the axial length with a concave inner surfaceand a convex outer surface, wherein the semi-cylindrical body is formedat a radius in a range of one to six centimeters, and the bodyterminates at circumferential ends of the body; a plurality of groovesformed on the convex outer surface of the body along the axial length,wherein each groove corresponds to an incremental axial length of thebody, and the grooves extend from one circumferential end of the body tothe other; a plurality of length stamps along the convex outer surfaceof the body, wherein each of the plurality of length stamps is adjacentto a corresponding groove and indicates a length along the bone cuttingtemplate; a proximal end; and a distal end, wherein the plurality oflength stamps comprises a first set of length stamps and a second set oflength stamps, the first set of length stamps increase in value from theproximal end to the distal end, and the first set of length stamps has afirst orientation relative to a first side of the bone cutting template,the second set of length stamps increase in value from the distal end tothe proximal end, the second set of length stamps has a secondorientation relative to a second side of the bone cutting template, andthe second orientation is opposite to the first orientation.
 2. The bonecutting template of claim 1, wherein the concave inner surface issemi-cylindrical in shape to approximate an outer cortex of a bone, andthe body has a radial thickness in a range of one to six centimeters. 3.The bone cutting template of claim 1, wherein the semi-cylindrical shapeof the body forms an arch having an angular displacement of one hundredand eighty degrees, and the body is substantially rigid.
 4. The bonecutting template of claim 1, wherein the semi-cylindrical shape of thebody forms an arch having an angular displacement of one hundred andtwenty degrees and the body is formed from a material selected from thegroup consisting of ceramic, collagen-ceramic, a degradable polymer, anda combination thereof.
 5. The bone cutting template of claim 1, whereinthe semi-cylindrical shape of the body forms an arch having an angulardisplacement of ninety degrees.
 6. The bone cutting template of claim 1,further comprising: a central opening formed in the body at an axialcenter of the body; and a bone cutting template handle configured toremovably engage the central opening.
 7. The bone cutting template ofclaim 6, wherein the bone cutting template handle comprises a grip on aproximal end thereof, a shaft extending from the grip, and a tip at adistal end of the shaft that is keyed to and complementary in shape tothe central opening for removable engagement therewith.
 8. The bonecutting template of claim 1, wherein the body is porous and furthercomprises a therapeutic agent.
 9. A kit for field use, comprising: a setof bone cutting templates, wherein each of the bone cutting templatescomprises: a body having an axis; an axial length; an axialcross-sectional shape that is semi-cylindrical along the axial lengthwith a concave inner surface and a convex outer surface; a proximal end;and a distal end, wherein each of the semi-cylindrical bodies is formedat a radius in a range of one to six centimeters, and the bodiesterminate at circumferential ends of the bodies; a plurality of groovesformed on the convex outer surface of the body along the axial length,wherein each groove corresponds to an incremental axial length of thebody, and the grooves extend from one circumferential end of the body tothe other: and a plurality of length stamps along the convex outersurface of the body, wherein each of the plurality of length stamps isadjacent to a corresponding groove and indicates a length along the bonecutting template, wherein the plurality of length stamps comprises afirst set of length stamps and a second set of length stamps, the firstset of length stamps increase in value from the proximal end to thedistal end, and the first set of length stamps has a first orientationrelative to a first side of the bone cutting template, the second set oflength stamps increase in value from the distal end to the proximal end,the second set of length stamps has a second orientation relative to asecond side of the bone cutting template, and the second orientation isopposite to the first orientation; and a bone cutting template handleconfigured to removably engage each of the bone cutting templates. 10.The kit of claim 9, wherein the concave inner surface of each of thebodies is semi-cylindrical in shape to approximate an outer cortex of abone, and each of the bodies has a radial thickness in a range of one tosix centimeters.
 11. The kit of claim 9, wherein each of thesemi-cylindrical shapes of the bodies forms an arch having an angulardisplacement that differs from other ones of the bodies, and the bodiesare substantially rigid.
 12. The kit of claim 11, wherein the angulardisplacement of each of the semi-cylindrical shapes of the bodiescomprises one of one hundred and eighty degrees, one hundred and twentydegrees, and ninety degrees, and the bodies are formed form a materialselected from the group consisting of ceramic, collagen-ceramic, adegradable polymer, and a combination thereof.
 13. The kit of claim 9,wherein each of the bodies further comprises: a central opening formedin the body at an axial center of the body for removable engagement bythe bone cutting template handle.
 14. The kit of claim 13, wherein thebone cutting template handle comprises a grip on a proximal end thereof,a shaft extending from the grip, and a tip at a distal end of the shaftthat is keyed and complementary in shape to the central opening forremovable engagement therewith.
 15. The kit of claim 9, wherein the bodyis porous and further comprises a therapeutic agent.